Synthesis of BILN 2061, an HCV NS3 Protease Inhibitor with Proven Antiviral Effect in Humans
Organic Letters2004Vol. 6(17), pp. 2901–2904
Citations Over TimeTop 10% of 2004 papers
Anne‐Marie Faucher, Murray D. Bailey, Pierre L. Beaulieu, Christian Brochu, Jean‐Simon Duceppe, Jean‐Marie Ferland, Élise Ghiro, Vida Gorys, Ted Halmos, Stephen H. Kawai, Martin Poirier, Bruno Simoneau, Youla S. Tsantrizos, Montse Llinàs‐Brunet
Abstract
The synthesis of BILN 2061, an NS3 protease inhibitor with proven antiviral effect in humans, was accomplished in a convergent manner from four building blocks. The procedure described here was suitable for the preparation of multigram quantities of BILN 2061 for preclinical pharmacological evaluation.
Related Papers
- → West Nile Virus (WNV) protease and membrane interactions revealed by NMR spectroscopy(2012)8 cited
- Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.(2008)
- → Identification of the protease domain in NS3 of hepatitis C virus(1995)38 cited
- → Protease and Protease Inhibitor Activity in Rat Skeletal Muscle during Growth, Protein Deficiency and Fasting(1974)5 cited
- → Preliminary Characterization of Protease Inhibitor from Bacteria-Associated with Sponge from Panggang Island, Seribu Islands(2006)